Tarsus Pharmaceuticals Q2 2024 GAAP EPS $(0.88) Beats $(0.94) Estimate, Sales $40.813M Beat $31.664M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tarsus Pharmaceuticals (NASDAQ:TARS) reported Q2 2024 GAAP EPS of $(0.88), beating the estimate of $(0.94). Sales were $40.813M, surpassing the $31.664M estimate.
August 08, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.88) beating the $(0.94) estimate and sales of $40.813M surpassing the $31.664M estimate.
The better-than-expected earnings and sales figures are likely to positively impact Tarsus Pharmaceuticals' stock price in the short term. Beating both EPS and sales estimates by significant margins indicates strong performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100